Huron Revenue Hit a Record $444 Million. So Why Did This Fund Trim Its Stake?

Aristotle Capital Boston sold 40,351 shares of Huron Consulting Group in Q1 2026, trimming its position by $18.29 million to 249,912 shares valued at $31.90 million. The filing suggests reduced exposure rather than a full exit, leaving Huron at 1.98% of fund AUM. The stock has fallen 30% over the past year, but the company reported 12% revenue growth to $443.7 million and reaffirmed full-year 2026 guidance.

Analysis

This looks more like disciplined de-risking than a bearish thesis shift. When an active holder trims a quality compounder after a sharp drawdown but still keeps it near 2% of AUM, the signal is usually valuation discipline and/or portfolio concentration control, not capitulation. The more important read-through is that the market may be punishing Huron for cyclical consulting beta even as fundamentals keep compounding, which creates a mismatch between operating momentum and investor positioning.

The second-order issue is mix. Huron’s strongest growth pockets are tied to healthcare and digital transformation, both of which are less discretionary than classic corporate strategy work, but still exposed to budget scrutiny if procurement teams slow project starts. That means the stock can re-rate quickly on evidence of backlog conversion and margin durability; conversely, any guide-down on utilization or mix would likely hit the multiple harder than the earnings change itself.

The contrarian opportunity is that HURN has already de-rated enough for good news to matter more than perfect execution. A business growing revenue in the low-teens with EBITDA expanding faster should not trade like a structurally challenged consultant unless investors expect a spending rollover, so the key catalyst is the next couple of quarters of sustained bookings and margin progression. The risk is that “AI consulting demand” is being over-credited by the market as a durable driver when in practice it can be a short-cycle project category that normalizes quickly.

Key Decisions for Investors

• Long HURN on weakness over the next 2-6 weeks if the stock remains below recent support; risk/reward improves if the market is pricing a cyclical slowdown while the company is still printing double-digit growth.
• Use a call spread in HURN rather than outright stock for a 3-6 month catalyst window; upside should come from multiple expansion if backlog and EBITDA margins stay firm, with defined downside if consulting spending softens.
• Pair trade: long HURN / short a more discretionary consulting beta name or broad consulting ETF exposure for 1-2 quarters; thesis is that HURN’s healthcare skew should hold up better if corporate project budgets tighten.
• Trim or hedge on any post-earnings gap-up unless management explicitly re-accelerates backlog conversion; the stock can rerate fast, but that also raises the probability of a short-term mean reversion.
• For sentiment investors, treat the Aristotle sale as neutral-to-slightly-positive for contrarians: a partial trim after a drawdown often removes incremental selling pressure without signaling a fundamental break.